Beacon Pointe Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Beacon Pointe Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,565	Closed	-$5.77M	–	1221
2024 Q4	$5.77M	Sell	17,565 -234	-1%	-$79.4K	0.06%	252
2024 Q3	$5.96M	Sell	17,799 -218	-1%	-$69.2K	0.07%	250
2024 Q2	$4.92M	Sell	18,017 -964	-5%	-$280K	0.06%	280
2024 Q1	$6.56M	Buy	+18,981	New	+$6.24M	0.07%	241
2023 Q2	–	Sell	-881	Closed	-$422K	–	1089
2023 Q1	$422K	Buy	881 +185	+27%	+$86.6K	0.01%	816
2022 Q4	$293K	Buy	+696	New	+$281K	0.01%	870
2022 Q2	–	Sell	-3,307	Closed	-$1.86M	–	1054
2022 Q1	$1.86M	Buy	3,307 +2,960	+853%	+$1.78M	0.03%	463
2021 Q4	$262K	Buy	347 +77	+29%	+$57.6K	0.01%	780
2021 Q3	$201K	Sell	270 -233	-46%	-$175K	0.01%	859
2021 Q2	$324K	Buy	+503	New	+$306K	0.01%	640

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Beacon Pointe Advisors's BIO Position: Q1 2025 in Review

Beacon Pointe Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 17,565 shares — an estimated $5.77M sold.

Beacon Pointe Advisors first reported a position in BIO in Q2 2021 and held it in 10 quarters. The position peaked at $6.56M in Q1 2024. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

Beacon Pointe Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
Beacon Pointe Advisors sold 17,565 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $5.77M.
Beacon Pointe Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 10 quarters.
Beacon Pointe Advisors's Bio-Rad Laboratories Class A position peaked at $6.56M in Q1 2024.
436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Beacon Pointe Advisors's 13F filing for Q1 2025, filed 13 May 2025.